Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $14
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $15 to $14.
Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $15 to $14.